Literature DB >> 10640674

Identification and localization of ataxin-7 in brain and retina of a patient with cerebellar ataxia type II using anti-peptide antibody.

C Mauger1, J Del-Favero, C Ceuterick, U Lübke, C van Broeckhoven, J Martin.   

Abstract

Autosomal dominant cerebellar ataxias (ADCAs) are a complex group of neurodegenerative disorders characterized by progressive degeneration of the cerebellum, brain stem and spinal cord. The spinocerebellar ataxia type 7 (SCA7) is associated with pigmentary macular dystrophy and retinal degeneration leading to blindness caused by a CAG/polyglutamine (polyGln) expansion in the coding region of the SCA7 gene/protein. The SCA7 gene codes for ataxin-7, a protein of unknown function. To investigate its cellular and subcellular localization, we have developed a sequence-specific polyclonal antibody against the N-terminal part of the protein. Immunohistochemical analysis indicated that ataxin-7 accumulates as single nuclear inclusion (NI) in the cells of the brain and retina of a SCA7 patient but not of controls. The 1C2 antibody, directed against expanded polyGln, confirmed the aggregation of mutant ataxin-7 in these NIs. Furthermore, ubiquitin was found in these aggregates, suggesting that mutant ataxin-7 is a target for ubiquitin-dependent proteolysis, but resistant to removal. Electron microscopic studies using immunogold labeling showed that ataxin-7 immunoreactive NIs appear as dense aggregates containing a mixture of granular and filamentary structures. Together, these data confirm the presence of NIs in brain and retina of a SCA7 patient, a common characteristic of disorders caused by expanded CAG/polyGln repeats.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10640674     DOI: 10.1016/s0169-328x(99)00256-9

Source DB:  PubMed          Journal:  Brain Res Mol Brain Res        ISSN: 0169-328X


  8 in total

Review 1.  Roles for the ubiquitin-proteasome pathway in protein quality control and signaling in the retina: implications in the pathogenesis of age-related macular degeneration.

Authors:  Fu Shang; Allen Taylor
Journal:  Mol Aspects Med       Date:  2012-04-10

2.  Somatic instability of expanded CAG repeats of ATXN7 in Japanese patients with spinocerebellar ataxia type 7.

Authors:  Satoshi Katagiri; Takaaki Hayashi; Tomokazu Takeuchi; Hisashi Yamada; Tamaki Gekka; Kiyokazu Kawabe; Akira Kurita; Hiroshi Tsuneoka
Journal:  Doc Ophthalmol       Date:  2015-02-03       Impact factor: 2.379

3.  Distribution and pattern of pathology in subjects with familial or sporadic late-onset cerebellar ataxia as assessed by p62/sequestosome immunohistochemistry.

Authors:  Maria Pikkarainen; Päivi Hartikainen; Hilkka Soininen; Irina Alafuzoff
Journal:  Cerebellum       Date:  2011-12       Impact factor: 3.847

Review 4.  Molecular Targets and Therapeutic Strategies in Spinocerebellar Ataxia Type 7.

Authors:  Anna Niewiadomska-Cimicka; Yvon Trottier
Journal:  Neurotherapeutics       Date:  2019-10       Impact factor: 7.620

5.  The androgen receptor's CAG/glutamine tract in mouse models of neurological disease and cancer.

Authors:  Andrew P Lieberman; Diane M Robins
Journal:  J Alzheimers Dis       Date:  2008-06       Impact factor: 4.472

Review 6.  The ubiquitin-proteasome system in retinal health and disease.

Authors:  Laura Campello; Julián Esteve-Rudd; Nicolás Cuenca; José Martín-Nieto
Journal:  Mol Neurobiol       Date:  2013-01-22       Impact factor: 5.590

7.  Comparison of an expanded ataxia interactome with patient medical records reveals a relationship between macular degeneration and ataxia.

Authors:  Juliette J Kahle; Natali Gulbahce; Chad A Shaw; Janghoo Lim; David E Hill; Albert-László Barabási; Huda Y Zoghbi
Journal:  Hum Mol Genet       Date:  2010-11-15       Impact factor: 6.150

Review 8.  The Molecular Basis of Spinocerebellar Ataxia Type 7.

Authors:  Rituparna Goswami; Abudu I Bello; Joe Bean; Kara M Costanzo; Bwaar Omer; Dayanne Cornelio-Parra; Revan Odah; Amit Ahluwalia; Shefaa K Allan; Nghi Nguyen; Taylor Shores; N Ahmad Aziz; Ryan D Mohan
Journal:  Front Neurosci       Date:  2022-03-24       Impact factor: 4.677

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.